Oncology and Hematology - Prova Education

Episodes 1-16 of 62

Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
MinuteCE®
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
MinuteCE®
Fixed-Duration: A Patient-Captivating Standard of Care in CLL
1.25 credits 10 episodes
- Talha Munir, PhD
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 credits 10 episodes
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
MinuteCE®
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
Combination Therapy for CLL: What Evidence Do We Have?
Combination Therapy for CLL: What Evidence Do We Have?
MinuteCE®
Combination Therapy for CLL: What Evidence Do We Have?
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
MinuteCE®
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
MRD Testing to Guide Treatment Considerations in CLL
MRD Testing to Guide Treatment Considerations in CLL
MinuteCE®
MRD Testing to Guide Treatment Considerations in CLL
1.25 program credits
- Talha Munir, PhD
1.25 program credits
Risk-Stratification in Newly Diagnosed CLL
Risk-Stratification in Newly Diagnosed CLL
MinuteCE®
Risk-Stratification in Newly Diagnosed CLL
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
MinuteCE®
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
MinuteCE®
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Mutational Testing to Guide Therapy in CLL: Why and When
Mutational Testing to Guide Therapy in CLL: Why and When
MinuteCE®
Mutational Testing to Guide Therapy in CLL: Why and When
1.25 program credits
- Talha Munir, PhD
1.25 program credits
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
MinuteCE®
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
CME/CE
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
1.00 credit
- Josep Tabernero, MD, PhD
- Sara Lonardi, MD
- Zev A. Wainberg, MD
1.00 credit
Advancements in GU Cancers: Key Data from AUA 2024
Advancements in GU Cancers: Key Data from AUA 2024
CME/CE
Advancements in GU Cancers: Key Data from AUA 2024
0.50 credits
- Jason Hafron, MD
- Carissa Chu. MD
0.50 credits
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
CME/CE
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
0.50 credits
- Javier Cortes, MD, PhD
- Komal Jhaveri, MD, FACP
0.50 credits
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME/CE
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
0.25 credits
- Jeffrey V. Matous, MD
0.25 credits
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME/CE
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
0.50 credits
- Jeffrey V. Matous, MD
- Donna Catamero, NP
- Ajai Chari, MD
0.50 credits

Prev
1
2
3
4
Next

1/4